NCT07188610 - PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2027

Conditions

CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma

Interventions

BIOLOGICAL

T cell injection targeting CD7 chimeric antigen receptor

After signing the informed consent form, eligible subjects will undergo a single nucleated cell collection for the preparation of CAR-T cells, followed by lymphodepletion pretreatment and a single infusion of PA3-17 injection.